Abstract
This open study was undertaken to assess the efficacy of clozapine in resistant schizophrenics, its side effects and safety profile and the mean dose required. Sample consisted of 28 patients who had been previously treated with neuroleptics and ECTs. A special proforma was prepared for recording the psychopathology and side effect profile. The complete blood count, differential count and BPRS scores were recorded weekly for a period of 3 months. Within 1 month of treatment on a dose range of 100-200 mg/day a 25%-50% decline in the BPRS score was noticed, the mean dose required was 241 mg/day. Sedation and sialorrhoea constituted the commonest side effects in 90% patients. No case of agranulocytosis was reported. The implications of the study are discussed.
Keywords: Clozapine, treatment resistant schizophrenia
Full Text
The Full Text of this article is available as a PDF (218.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anderman B., Griffith R. W. Clozapine-induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharmacol. 1977 Mar 11;11(3):199–201. doi: 10.1007/BF00606410. [DOI] [PubMed] [Google Scholar]
- Breier A., Buchanan R. W., Irish D., Carpenter W. T., Jr Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry. 1993 Dec;44(12):1145–1149. doi: 10.1176/ps.44.12.1145. [DOI] [PubMed] [Google Scholar]
- Fitton A., Heel R. C. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs. 1990 Nov;40(5):722–747. doi: 10.2165/00003495-199040050-00007. [DOI] [PubMed] [Google Scholar]
- Kane J. M. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry Suppl. 1992 May;(17):41–45. [PubMed] [Google Scholar]
- Kane J. M. Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential. Drugs. 1993 Oct;46(4):585–593. doi: 10.2165/00003495-199346040-00002. [DOI] [PubMed] [Google Scholar]
- Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988 Sep;45(9):789–796. doi: 10.1001/archpsyc.1988.01800330013001. [DOI] [PubMed] [Google Scholar]
- Kay S. R., Opler L. A., Lindenmayer J. P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988 Jan;23(1):99–110. doi: 10.1016/0165-1781(88)90038-8. [DOI] [PubMed] [Google Scholar]
- Klik J., Krausová J., Krízová J., Mareesová H., Vencovský E. Zkusenosti s clozapinem v praxi psychiatrické lécebny. Cesk Psychiatr. 1976 Jun;72(3):197–200. [PubMed] [Google Scholar]
- Lindström L. H. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand. 1988 May;77(5):524–529. doi: 10.1111/j.1600-0447.1988.tb05164.x. [DOI] [PubMed] [Google Scholar]
- Mattes J. A. Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years. J Clin Psychiatry. 1989 Oct;50(10):389–391. [PubMed] [Google Scholar]
- Umbricht D. S., Pollack S., Kane J. M. Clozapine and weight gain. J Clin Psychiatry. 1994 Sep;55 (Suppl B):157–160. [PubMed] [Google Scholar]